26 August 2024 - Faron Pharmaceuticals today announces that their lead candidate bexmarilimab has been granted fast track designation for the treatment of relapsed or refractory myelodysplastic syndrome in combination with azacitidine by the US FDA.

Given the previously reported promising results in both Phase 1 and 2 of Faron's BEXMAB trial when treating relapsed or refractory myelodysplastic syndrome patients using a combination of bexmarilimab and azacitidine to overcome primary or developed resistance to azacitidine, bexmarilimab has been granted fast track designation subsequent to the accelerated development plan proposed by the FDA in July 2024.

Read Faron Pharmaceuticals press release